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Abstract
INTRODUCTION
Soluble Galectin-1 (sGal-1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been 
reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). 
We aimed to determine the clinical utility of these biomarkers  for evaluation of treatment 
response compared to CCL17/Thymus and Activation Regulated Chemokine (TARC). 
MATERIALS AND METHODS
Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients 
before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with 
disease characteristics and clinical treatment response. 
RESULTS
Elevated plasma levels of sGal-1, sCD163, sCD30 and TARC were found in 67%, 21%, 91% 
and 93% of cHL patients respectively. Mean plasma levels of sGal-1 and sCD30 decreased 
after treatment and sCD163 did not decrease after treatment. There was no correlation with 
change of these markers and clinical treatment response on individual patient level. TARC levels 
strongly correlated with disease characteristics and metabolic volume. TARC remained high in 6 
out of 7 non-responsive patients and dramatically decreased in 95 out of 96 responsive patients.
CONCLUSION
In summary, elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found 
in patients with cHL. However, only plasma TARC accurately reflects disease activity and 
correlates with clinical treatment response.
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Introduction
Classical Hodgkin lymphoma (cHL) is currently a highly curable disease. More than 85 percent of 
patients become long-term survivors with current treatment strategies (Ansell, 2012). Current 
clinical studies focus on preventing long-term toxicity in patients who do not need intensive 
regimens and on early recognition of patients not optimally responding to initial treatment. 
Testing for chemosensitivity using [18F]-fluoro-2-deoxy-D-glucose positron emission 
tomography (FDG-PET) early during treatment is often part of this strategy. Because of a lack 
of accurate pre-treatment predictive factors, early FDG-PET response is currently the best 
predictor for final response to treatment.1-4 
Blood based biomarkers hold the promise to be much more practical, patient friendly and cost-
effective and might be used as serial markers during and after treatment to determine early 
response to treatment and disease recurrence after treatment. However, such markers must 
have specificity and sensitivity at least comparable or complementary to FDG-PET imaging and 
must be able to accurately distinguish cHL patients from controls at the individual patient level. 
Several candidate biomarkers have been reported to be elevated in patients with cHL compared 
to healthy controls. These biomarkers can be divided into tumor cell specific markers, secreted 
by Hodgkin Reed-Sternberg (HRS) cells or markers related to the micro-environment.5,6 
We and others have previously shown that the HRS cell specific CC chemokine ligand 17 
(CCL17, also Thymus and Activation Regulated Chemokine (TARC)) is a very specific marker 
for cHL disease activity.7-12 TARC levels correlate with metabolic tumor volume as determined 
by FDG-PET imaging and can already determine response to treatment after one cycle of 
chemotherapy.10,11 Similar to FDG-PET imaging, high TARC levels after treatment correlate 
with reduced survival.12,13
Meanwhile other groups have demonstrated that the soluble form of tumor cell specific marker 
Galectin-1 (sGal-1) and the M2 macrophage marker soluble CD163 (sCD163) are elevated in 
serum of patients with cHL.11,14 Also soluble CD30 (sCD30) has been reported to correlate with 
disease extensiveness and prognosis in cHL. 15-19 However, there are no data on measurements 
of sGal-1 and sCD30 before and after treatment and data on serial measurements of sCD163 
are scarce. The aim of the current study was to compare the clinical value of serial measurements 
of these markers before and after treatment with TARC for the evaluation response in a well-
defined cohort of cHL patients.
56   |   Chapter 3
Materials and methods
Patient inclusion
We included all newly diagnosed cHL patients in the University Medical Center Groningen 
(UMCG) from January 2006 until December 2014 in whom plasma or serum samples were 
collected. In total, 103 cHL patients were included. From 63 of these patients TARC data have 
been reported previously 10. Permission for this study was obtained from the institutional review 
board of the UMCG and all participating patients and healthy controls signed informed consent.
Staging en response determination
All patients were staged and evaluated with FDG-PET imaging with or without additional bone 
marrow biopsy. Response to treatment was evaluated by PET/CT according to the revised 
International Working Group response criteria. 20,21 All FDG-PET scans were reviewed and 
scored according to the Lugano classification including Deauville score.22 In case of doubtful 
remission status after completion of treatment, suspicious lesions were either biopsied or 
followed for progression with repeated imaging.
Patients were either included or generally treated according to the standard of arm of European 
Organisation for Research and Treatment of Cancer (EORTC) clinical trial protocols (Table 1). 
In short, treatment for early stage patients consisted of 3-6 cycles of ABVD with or without 
30-36 Gy involved node radiotherapy (IN-RT) according to the EORTC (20051) H10 trial in 
the vast majority of patients.23 Advanced stage patients were mainly treated with 6-8 cycles of 
ABVD, or 4 cycles of dose escalated BEACOPP (escBEACOPP) followed by 4 cycles of normal 
dose BEACOPP, or -more recently- with 6 cycles of escBEACOPP. Advanced stage patients with 
FDG-PET positive disease after chemotherapy received additional involved node radiotherapy 
(INRT) on PET positive residual disease.
Mid-treatment FDG-PET was planned after 2 cycles of ABVD for early stage patients, or after 4 
cycles of ABVD, or 3 or 4 cycles of (Esc)BEACOPP for advanced stage patients respectively. In 
case of complete metabolic response, i.e. no suspicious uptake on the mid-treatment FDG-PET 
scan (Deauville 1), FDG-PET scan was not routinely repeated at end of treatment for early stage 
patients. Determination of metabolic tumor volume has been assessed as previously described.10
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Table 1. Patient characteristics
cHL patients (n=103)
n (%)






cHL NOS 22 (21)
Ann Arbor stage
I-II (early stage) 61 (59)
III-IV (advanced stage) 42 (41)
B-symptoms present 44 (43)
Bulky disease 30 (30)
Treatment stage I/II patients (n=61):
ABVD 3-4 cycles + IN-RT 43 (70)
ABVD 4-6 cycles 15 (25)
ABVD 2 cycles, EscBEACOPP 2 cycles + IN-RT 2 (3)
Other 1 (2)
Treatment stage III/IV patients (n=42):
ABVD 6-8 cycles +/- RT 23 (55)
(Esc)BEACOPP 6-8 cycles +/- RT 12 (29)
Other 7 (17)
NS = nodular sclerosis; MC = Mixed cellularity; LR = Lymphocyte Rich; cHL = classical Hodgkin Lymphoma; 
NOS = not otherwise specified; ABVD = adriamycin-bleomycin-vinblastine-dacarbazine containing 
chemotherapy regimen; IN-RT = involved node radiotherapy; BEACOPP = bleomycin-etoposide-
adriamycin-cyclophosphamide-vincristine-procarbazine-prednisone containing chemotherapy regimen; 
EscBEACOPP = escalated (dose intensified) BEACOPP.
Sample collection and ELISA
From all 103 patients plasma or serum samples were collected before and after treatment. 
Plasma samples were obtained from 76 patients before treatment and 75 patients after 
treatment, serum before and after treatment in 27 and 28 patients respectively. Plasma 
collected from 107 age and sex matched healthy controls and serum from 25 controls out of 
the same control cohort, were used for comparison with the pre-treatment patient samples and 
determination of cut-offs.
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Levels of sGal-1, sCD163, sCD30 and TARC were measured by a double antibody sandwich 
ELISA (all R&D Systems, Minneapolis, MN, USA) according to the manufacturers’ instructions. 
Samples were analyzed without prior knowledge of the corresponding patient or treatment 
results. 
Statistics
Optimal biomarker cut off levels between patients and healthy controls were determined 
using the Receiver Operating Characteristic method. Differences in biomarker levels between 
categorical variables were calculated using the unpaired t-test. Baseline biomarker levels 
were correlated to Ann Arbor stage using the analysis of variance (ANOVA) method and 
Tukey’s Multiple Comparison test as post-hoc test. Correlation between biomarker levels and 
the metabolic tumor volume determination by FDG-PET were calculated using the Pearson 
correlation test. All statistical analyses were performed using GraphPad Prism version 5.04 for 
Windows (GraphPad Software, San Diego California USA, www.graphpad.com). The p-value for 
statistical significancy was defined at .05.
Correlation of biomarker levels with disease characteristics was performed using the results 
of plasma samples exclusively. The number of serum samples was not sufficient for reliable 
correlation analysis.




Basic characteristics and treatments of the 103 newly diagnosed cHL patients are summarized 
in Table 1. Median age of the patient cohort was 34 years (range 16-82) and there were slightly 
more females than males. Most patients had nodular sclerosis subtype.
Pre-treatment biomarker levels compared to controls
We found significantly different levels for sGal-1 and TARC in plasma versus serum in controls 
(Figure 1). Because of these differences, results for plasma and serum are analyzed and shown 
separately for all biomarkers. 
Compared to controls, cHL patients had significantly higher mean levels for sGal-1 (26.5 vs. 45.8 
ng/ml (p < .001)), sCD163 (469 vs. 646 ng/ml for sCD163 (p = .003)), sCD30 (1.8 vs. 4.6 ng/ml 
for sCD30 (p < .001)) and TARC (134 vs. 54 161 pg/ml (p < .001)) in plasma samples at diagnosis 
(Figure 1, Table 2). Fold difference of the mean for sGal-1, sCD163 and sCD30 were modest 
with 1.7, 1.4 and 2.6 respectively, whereas the difference of the mean was 404 fold for TARC. 
ROC analysis performed on plasma samples showed most discriminative values for sCD30 and 
TARC with areas under the curve for sGal-1, sCD163, sCD30 and TARC of 0.85, 0.55, 0.95 and 
0.97 respectively (Table 2, Supporting Figure 1). Cut-off levels with most optimal sensitivity and 
specificity showed elevated levels of sGal-1 (>35 ng/ml), sCD163 (>617 ng/ml), sCD30 (> 2.7 
ng/ml) and TARC (>635 pg/ml) in 67%, 21%, 91% and 93% of patients respectively.
Serum levels were also significantly different in these markers, expect for sCD30 in which serum 
levels of sCD30 were lower compared to controls in a proportion of patients (Figure 1). 
Correlation with disease characteristics
Plasma sGal-1, sCD163 and sCD30 levels did not significantly correlate with disease stage or 
metabolic tumor volume (Figure 2), whereas TARC levels were significantly higher in stage IV 
compared to stage I or II disease (p < .001, Figure 2D). TARC levels also significantly correlated 
with metabolic tumor volume (r2=.40, p<.001; Figure 2H). Higher TARC levels were observed 
in patients with bulky disease (p = .003), B-symptoms (p = .001) and early stage unfavorable 
disease (p = .03). No correlation of TARC with International Prognostic Score in patients with 
advanced disease was found (Table 2, Supporting Figure 2). 
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Figure 1. Plasma and serum biomarker levels in cHL patients and healthy controls. sGal-1 (A) and 
sCD163 (B) levels are significantly elevated in patients with cHL both in plasma and serum samples, 
with elevation of plasma samples in 67% and 21% of patients respectively. sCD30 (C) showed significant 
elevation in plasma samples of patients compared to controls, with 91% of samples being elevated (C). 
Serum samples among a proportion of patients were low for sCD30. TARC levels among patients with 
cHL were significantly elevated compared to controls in both plasma and serum (D). Ninety-three percent 
of cHL patients show elevated plasma samples before start of treatment. 
For sGal-1 and sCD30 no correlation with bulky disease, B-symptoms, unfavorable disease in 
early stage patients and high International Prognostic Score in advanced stage patients was 
found (Table 2, Supporting Figure 2). High sCD163 levels only significantly correlated with 
presence of B-symptoms (p <.001). 
Figure 2. Plasma biomarker levels compared to parameters of disease extensiveness. Pre-treatment 
plasma levels of sGal-1, sCD163, sCD30 and TARC among cHL patients stratified by stage of disease (A-
D) and metabolic tumor volume (E-H). Only TARC (D) levels are significantly higher among higher disease 
stages and correlated with metabolic tumor volume as measured by quantification of pre-treatment FDG-
PET images. ▶
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Table 2. Comparison of plasma biomarker characteristics
sGal-1 sCD163 sCD30 TARC
Mean level controls (SD) 26.5 (11.4) 469 (186) 1.8 (2.0) 134 (90)
Mean level patients (SD) 45.8 (17.3) 646 (561) 4.6 (2.5) 54 161 
(65 037)
AUC plasma controls vs. patients 0.85 0.55 0.95 0.97
Upper limit of normal 35 617 2.7 635
Elevated pre-treatment (%) 67 21 91 93
Significantly higher in advanced disease stages - - - +
Correlation with metabolic tumor volume - - - +
Significantly elevated in patients with:
- bulky disease - - - +
- B-symptoms - + - +
- unfavorable disease* (early stage patients) - - - +
- IPS≥3 (advanced stage patients) - - - -
Correlation with treatment response - - - +
* Unfavorable disease was determined using the European Organization for Research and Treatment 
of Cancer risk assessment. SD = standard deviation; AUC = Area under the curve; IPS = international 
prognostic score. 
Correlation with treatment response
Out of 103 patients, 96 (93%) achieved a complete remission by first line treatment, and seven 
patients failed first line therapy: six had an FDG-PET positive (Deauville ≥4) partial response 
and one had FDG-PET positive progressive disease (Deauville 5). 
Mean plasma levels of sGal-1, sCD30 and TARC significantly decreased after treatment 
compared to pre-treatment (Figure 3). Plasma levels of sCD163 significantly increased after 
treatment and serum levels of sCD163 significantly decreased after treatment. Serum levels of 
TARC also significantly decreased after treatment while changes in serum levels of Gal-1 and 
sCD30 after treatment were not significant.
sGal-1 levels decreased in almost all patients including four out of seven patients that failed 
treatment (Fig 3A). sCD163 did not show any consistent correlation with treatment response 
(Fig 3B) and sCD30 was lower in almost all patients after treatment including four non-responsive 
patients (Fig 3C). In contrast, TARC dramatically decreased in 95 out of 96 responsive patients 
and remained high in 6 out of 7 non-responsive patients (Fig 3D). The single patient in complete 
remission with high post-treatment TARC levels had active atopic dermatitis.
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Figure 3. Biomarker levels before and after treatment. 
sGal-1 levels significantly decreased after treatment for plasma samples, while there was no significant 
decrease among serum samples (A). sCD163 plasma levels significantly increased after treatment while 
serum levels significantly decreased (B). sCD30 levels significantly decreased after treatment in plasma 
samples while the decrease in serum was not significant (C). TARC significantly decreased after treatment 
in both plasma and serum samples (D). On individual patient level only TARC levels show clear separation 
between responsive and non-responsive patients. 
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Discussion
The aim of this study was to evaluate two recently published blood biomarkers, i.e. sGal-1 and 
sCD163, as treatment response biomarkers and compare their performance to sCD30 and 
TARC in a well-defined cohort of cHL patients. 
We found that sGal-1, sCD163, sCD30 and TARC levels were elevated in cHL patients compared 
to healthy controls consistent with previous studies.10,11,14-16 sCD30 and TARC had better 
discriminative power in separating patients from controls compared to sGal-1 and sCD163. 
Although levels of sGal-1, sCD163 and sCD30 significantly changed after treatment, only TARC 
corresponded consistently with clinical treatment response at the individual patient level.
Our pre-treatment sGal-1 results are in part consistent with the publication by Ouyang et 
al.14 They reported elevation of sGal-1 in serum of cHL patients and we confirmed this finding 
both in plasma and serum samples. We could not confirm the correlation of sGal-1 with clinical 
parameters of disease extensiveness such as presence of bulky disease, B-symptoms, stage 
of disease or metabolic tumor volume. Although the results might be influenced by the use of 
plasma in our study as compared to serum in the study of Ouyang et al, levels in serum were 
lower compared to plasma in our cohort. This makes it unlikely that serum would be more 
sensitive than plasma.
For sCD163, part of our results is consistent with a previous report with serial sCD163 
measurements.11 They showed a gradual decrease of sCD163 during and after treatment 
in serum samples of cHL patients. We could observe a similar pattern in our serum samples, 
while in plasma we observed a slight increase in sCD163 levels in post-treatment samples. 
This increase might reflect treatment induced inflammatory responses including activation of 
macrophages.24 sCD163 has been reported to be elevated in several inflammatory conditions 
such as sepsis, diabetes, liver cirrhosis, rheumatoid arthritis, HIV and macrophage activation 
syndrome. However, this does not explain the different patterns observed in plasma versus 
serum samples. Jones et al. also found a correlation between serum sCD163 and interim 
response. It must be stressed out that there was a large overlap between patients in complete 
compared to partial remission in their cohort. This makes CD163 less useful as a biomarker for 
response evaluation at the individual patient level. 
The sCD30 results are consistent with the studies by Nadali et al..15,16 In addition to elevated 
sCD30 levels in cHL patients compared to controls, they reported correlations with stage, bulky 
disease and B symptoms. We could not confirm these associations but did find a significant 
decrease in sCD30 levels after treatment. 
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 the current study. Markers that are mainly produced by cells in the infiltrate, like sCD163 by 
macrophages, are less likely to be disease specific. Elevated levels of sCD163 are for example 
found in many different types of diseases.25-27 Also sGal-1 is found in many tissues and tumor 
types and elevated sGal-1 levels can be found in serum of patients with head and neck squamous 
cell carcinoma, glioma, thyroid disease and systemic sclerosis.28-31 In contrast, sCD30 and TARC 
are almost exclusively produced by HRS cells. In line with their tumor cells specificity we found 
elevated levels of sCD30 and TARC in 91% and 93% of patients respectively.
High levels of sCD30 but also high levels of TARC, IL-1RA, ICAM1, IL-6 and IL-2R and others have 
been correlated with an adverse prognosis.15-19 Pre-treatment sGal-1 and sCD163 levels might 
correlate with prognosis as well. The event rate in our cohort was too low to reliably correlate 
pre-treatment biomarker levels with disease outcome. Well known non-specific blood markers 
like hemoglobin, lymphocyte count, albumin and erythrocyte sedimentation rate are already 
included as prognostic factors in the International Prognostic Score (IPS) and future clinical 
trials should investigate the additive prognostic value of these new biomarkers.
The cohort we used in the current study is an expansion of the cohort that we previously used 
for TARC measurements.10 Consistent with our previous study, higher TARC levels correlated 
with higher disease stage, presence of B-symptoms, bulky disease and metabolic tumor volume. 
In this larger cohort now containing an additional number of four non responsive patients we 
could confirm the highly significant correlation of TARC with treatment response. Similar to our 
study Jones et al also found elevated levels of TARC before treatment and a good correlation of 
TARC with clinical treatment response.11 A recent study by Moskowitz et al. also showed that 
interim TARC normalization could predict PET negativity and superior event free survival in 
patients with relapsed or refractory cHL treated with brentuximab-vedotin.12
In conclusion, elevated levels of sGal-1, sCD163 and sCD30 were found in cHL patients but 
these markers could not discriminate patients from controls as accurately as TARC. Only serial 
TARC levels accurately reflect disease activity and correlate with clinical treatment response 
in individual patients. Future studies should elucidate whether TARC might partially replace 
interim or end-treatment FDG-PET imaging.
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Supporting Figure 1. Receiver Operating Characteric curves for sGal-1 (A), sCD163 (B), sCD30 (C) 
and TARC (D).









































































































































































































Supporting Figure 2. sGal-1, sCD163, sCD30 and TARC levels according to presence of bulky disease 
(A-D), B-symptoms (E-H) or IPS score among advanced stage patients (I-L).

